Hocker James R, Postier Russell G, Li Min, Lerner Megan R, Lightfoot Stan A, Peyton Marvin D, Deb Subrato J, Baker Candace M, Williams Travis L, Hanas Rushie Jane, Stowell Donald E, Lander Theresa J, Brackett Daniel J, Hanas Jay S
Department of Biochemistry & Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Cancer Lett. 2015 Apr 10;359(2):314-24. doi: 10.1016/j.canlet.2015.01.035. Epub 2015 Jan 28.
Blood tests are needed to aid in the early detection of pancreatic ductal adenocarcinoma (PDAC), and monitoring pancreatitis development into malignancy especially in high risk patients. This study exhibits efforts and progress toward developing such blood tests, using electrospray-mass spectrometry (MS) serum profiling to distinguish patients with early-stage PDAC or pancreatitis from each other and from controls. Identification of significant serum mass peak differences between these individuals was performed using t tests and "leave one out" cross validation. Serum mass peak distributions of control individuals were distinguished from those of patients with chronic pancreatitis or early-stage PDAC with P values <10(-15), and patients with chronic pancreatitis were distinguished from those of patients with early-stage PDAC with a P value <10(-12). Sera from 12 out of 12 patients with PDAC stages I, IIA and IIB were blindly validated from controls. Tandem MS/MS identified a cancer phenotype with elements of PDAC involved in early-stage PDAC/control discrimination. These studies indicate electrospray-MS mass profiling can detect serum changes in patients with pancreatitis or early-stage pancreatic cancer. Such technology has the potential to aid in early detection of pancreatic cancer, biomarker development, and in monitoring development of pancreatitis into PDAC.
需要进行血液检测以帮助早期发现胰腺导管腺癌（PDAC），并监测胰腺炎尤其是高危患者发展为恶性肿瘤的情况。本研究展示了在开发此类血液检测方面所做的努力和取得的进展，使用电喷雾质谱（MS）血清谱分析来区分早期PDAC患者或胰腺炎患者与对照组。使用t检验和“留一法”交叉验证来确定这些个体之间血清质谱峰的显著差异。对照组个体的血清质谱峰分布与慢性胰腺炎患者或早期PDAC患者的血清质谱峰分布有显著差异，P值<10（-15），慢性胰腺炎患者与早期PDAC患者的血清质谱峰分布有显著差异，P值<10（-12）。对12例I期、IIA期和IIB期PDAC患者的血清进行盲法验证，与对照组区分开来。串联质谱/质谱鉴定出一种癌症表型，其元素参与早期PDAC/对照组的区分。这些研究表明，电喷雾-MS质谱分析可以检测胰腺炎患者或早期胰腺癌患者的血清变化。这种技术有可能有助于早期发现胰腺癌、生物标志物的开发，以及监测胰腺炎发展为PDAC的情况。
